Alpha-2 agonists: Difference between revisions
Neil.m.young (talk | contribs) (Text replacement - "alpha" to "α") |
(add References section) |
||
| (2 intermediate revisions by 2 users not shown) | |||
| Line 4: | Line 4: | ||
==Medications== | ==Medications== | ||
*[[clonidine]] | *[[clonidine]] | ||
*[[dexmedetomidine]] | |||
*[[guanabenz]] | *[[guanabenz]] | ||
*[[guanfacine]] | *[[guanfacine]] | ||
*[[methyldopa]] | *[[methyldopa]] | ||
*[[moxonidine]] | *[[moxonidine]] | ||
*[[Xylazine toxicity|Xylazine]] (veterinary med, drug of abuse) | |||
==Adverse effects== | ==Adverse effects== | ||
| Line 16: | Line 18: | ||
==See Also== | ==See Also== | ||
*[[Antihypertensives]] | *[[Antihypertensives]] | ||
==References== | |||
<references/> | |||
[[Category:Pharmacology]] | [[Category:Pharmacology]] | ||
Latest revision as of 08:46, 22 March 2026
Background
- Central α agonists lower blood pressure by stimulating α-receptors in the brain which causes peripheral vasodilation
Medications
- clonidine
- dexmedetomidine
- guanabenz
- guanfacine
- methyldopa
- moxonidine
- Xylazine (veterinary med, drug of abuse)
Adverse effects
- sedation
- drying of the nasal mucosa
- rebound hypertension